Chennai– Pharma major Cadila Healthcare Ltd. on Monday said it has received the final approval from the US Food and Drug Administration (USFDA) to market metronidazole tablets.
In a regulatory filing with BSE, Cadila Healthcare said it has got USFDA’s approval to market metronidazole in strengths 250 mg and 500 mg tablets.
The drug is used to treat infections caused by bacteria or parasites.
According to Cadila Healthcare, the tablets will be made at the group’s formulations manufacturing facility at Baddi in Himachal Pradesh.
The company said the group now has more than 105 approvals and has so far filed nearly 275 ANDAs (Abbreviated New Drug Application) since the commencement of the filing process in FY 2003-04.
